MISC 6. Endovascular Therapy for Subclavian Artery Aneurysm and its Long-term Outcomes
Fei Liu,Wei Zhang,Xiaolong Shu,Daqiao Guo,Lixin Wang,Weiguo Fu
DOI: https://doi.org/10.1016/j.jvs.2019.08.165
IF: 4.86
2019-01-01
Journal of Vascular Surgery
Abstract:The objective of this study was to report our experience of endovascular therapy for subclavian artery aneurysm (SAA) as well as its long-term outcomes. A total of 34 patients (19 men; mean age, 51 years) with SAA (27 true aneurysms, 5 pseudoaneurysms, and 2 chronic dissected aneurysms) underwent successful endovascular procedures in our center from 2008 to 2018. The demographics and procedural details were retrospectively reviewed. Postoperative complications and long-term outcomes were followed up with clinical evaluation, ultrasound, or computed tomography. Embolization of the aneurysm without stent was performed in one patient. A total of 50 stents were used for the remaining 33 patients, with one stent for 19 SAAs (57.6%), two stents for 10 SAAs (30.3%), and three stents for 4 SAAs (12.1%). Parallel stents, in which one was placed in the right subclavian artery (RSA) and the other in the right common carotid artery (RCCA), were used in four patients with right SAA. Identifying the RSA origin, measuring the landing zone, and releasing the stent were performed on the tangential position of RSA and RCCA to avoid accidental coverage of the RCCA. Completion angiography showed nine type I endoleaks (26.5%) and one type II endoleak (2.9%). Type I endoleaks were treated with balloon dilation and additional stents, and all type I endoleaks resolved after this management. Type II endoleak in one patient was left without reintervention, and follow-up computed tomography angiography showed that it disappeared at 6 months. Twenty-nine patients (85.3%) with an average follow-up time of 70.7 months (range, 6-123 months) are still alive with patent stents. Three patients (9.1%) had intimal hyperplasia at 12, 24, and 72 months after the procedure, respectively. One patient (3.0%) had in-stent restenosis at 30 months. One patient (3.0%) underwent reintervention 48 months postoperatively for a dissecting aneurysm at the distal end of the primary stent. No other severe complications were found during the follow-up. With careful evaluation of lesions and election of strategies, endovascular treatment is a safe and effective therapeutic option for repairing SAA. Long-term outcomes are encouraging, with a low rate of endoleak and a high rate of stent patency.